66 related articles for article (PubMed ID: 30557986)
41. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
42. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics.
Dhanasekaran R; Limaye A; Cabrera R
Hepat Med; 2012 May; 4():19-37. PubMed ID: 24367230
[TBL] [Abstract][Full Text] [Related]
43. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.
Timek DT; Shi J; Liu H; Lin F
Am J Clin Pathol; 2012 Aug; 138(2):203-10. PubMed ID: 22904131
[TBL] [Abstract][Full Text] [Related]
44. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.
Uchino K; Tateishi R; Shiina S; Kanda M; Masuzaki R; Kondo Y; Goto T; Omata M; Yoshida H; Koike K
Cancer; 2011 Oct; 117(19):4475-83. PubMed ID: 21437884
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Yoo DJ; Kim KM; Jin YJ; Shim JH; Ko GY; Yoon HK; Sung KB; Lee JL; Kang YK; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2011 Jan; 26(1):145-54. PubMed ID: 21175808
[TBL] [Abstract][Full Text] [Related]
46. Liver cancer epidemic in China: past, present and future.
Chen JG; Zhang SW
Semin Cancer Biol; 2011 Feb; 21(1):59-69. PubMed ID: 21144900
[TBL] [Abstract][Full Text] [Related]
47. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.
Yan BC; Gong C; Song J; Krausz T; Tretiakova M; Hyjek E; Al-Ahmadie H; Alves V; Xiao SY; Anders RA; Hart JA
Am J Surg Pathol; 2010 Aug; 34(8):1147-54. PubMed ID: 20661013
[TBL] [Abstract][Full Text] [Related]
48. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma.
Yasuda E; Kumada T; Toyoda H; Kaneoka Y; Maeda A; Okuda S; Yoshimi N; Kozawa O
Hepatol Res; 2010 May; 40(5):477-85. PubMed ID: 20374302
[TBL] [Abstract][Full Text] [Related]
49. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
50. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
51. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.
Kakar S; Gown AM; Goodman ZD; Ferrell LD
Arch Pathol Lab Med; 2007 Nov; 131(11):1648-54. PubMed ID: 17979482
[TBL] [Abstract][Full Text] [Related]
52. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Shirakawa H; Jeong SC; Yamashina K; Hiramatsu A; Kodama H; Takahashi S; Chayama K
World J Gastroenterol; 2007 Jan; 13(3):414-20. PubMed ID: 17230611
[TBL] [Abstract][Full Text] [Related]
53. Clinical features of hepatocellular carcinoma with extrahepatic metastases.
Natsuizaka M; Omura T; Akaike T; Kuwata Y; Yamazaki K; Sato T; Karino Y; Toyota J; Suga T; Asaka M
J Gastroenterol Hepatol; 2005 Nov; 20(11):1781-7. PubMed ID: 16246200
[TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma presenting as bone metastasis.
Liaw CC; Ng KT; Chen TJ; Liaw YF
Cancer; 1989 Oct; 64(8):1753-7. PubMed ID: 2477134
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases.
Chen D; Li Z; Song Q; Qian L; Xie B; Zhu J
Medicine (Baltimore); 2018 Dec; 97(50):e13356. PubMed ID: 30557986
[TBL] [Abstract][Full Text] [Related]
56. Hepatocellualar carcinoma serum markers.
Bertino G; Ardiri A; Malaguarnera M; Malaguarnera G; Bertino N; Calvagno GS
Semin Oncol; 2012 Aug; 39(4):410-33. PubMed ID: 22846859
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
[TBL] [Abstract][Full Text] [Related]
58. Tumour markers in diagnosis and management.
Warnes TW; Smith A
Baillieres Clin Gastroenterol; 1987 Jan; 1(1):63-89. PubMed ID: 2437983
[TBL] [Abstract][Full Text] [Related]
59. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
60. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma.
Filmus J; Capurro M
Mol Diagn; 2004; 8(4):207-12. PubMed ID: 15887976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
